PDCD1 and hepatocellular carcinoma: KEYNOTE 524 is a phase I clinical trial evaluating the efficacy of a combination therapy using lenvatinib, a multiple receptor tyrosine kinase inhibitor, plus pembrolizumab, an anti-PD-1 therapy, in patients with advanced unresectable HCC with no prior systemic therapy.